The ethics of placebo-controlled trials: Methodological justifications

被引:70
|
作者
Millum, Joseph [1 ,2 ]
Grady, Christine [1 ]
机构
[1] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA
[2] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA
关键词
Ethics; Placebo control; Randomized controlled trial; HUMAN-IMMUNODEFICIENCY-VIRUS; DEVELOPING-COUNTRIES; CLINICAL-RESEARCH; CARE DEBATE; TRANSMISSION; ZIDOVUDINE; STANDARD;
D O I
10.1016/j.cct.2013.09.003
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The use of placebo controls in clinical trials remains controversial. Ethical analysis and international ethical guidance permit the use of placebo controls in randomized trials when scientifically indicated in four cases: (1) when there is no proven effective treatment for the condition under study; (2) when withholding treatment poses negligible risks to participants; (3) when there are compelling methodological reasons for using placebo, and withholding treatment does not pose a risk of serious harm to participants; and, more controversially, (4) when there are compelling methodological reasons for using placebo, and the research is intended to develop interventions that can be implemented in the population from which trial participants are drawn, and the trial does not require participants to forgo treatment they would otherwise receive. The concept of methodological reasons is essential to assessing the ethics of placebo controls in these controversial last two cases. This article sets out key considerations relevant to considering whether methodological reasons for a placebo control are compelling. Published by Elsevier Inc.
引用
收藏
页码:510 / 514
页数:5
相关论文
共 50 条
  • [31] The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial
    Phaik Yeong Cheah
    Norbert Steinkamp
    Lorenz von Seidlein
    Ric N. Price
    BMC Medical Ethics, 19
  • [32] Placebo controlled trials in neuromyelitis optica are needed and ethical
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (06) : 536 - 545
  • [33] Randomized Placebo-Controlled Placebo Trial to Determine the Placebo Effect Size
    Gerdesmeyer, Ludger
    Klueter, Tim
    Rahlfs, Volker W.
    Al Muderis, Munjed
    Saxena, Amol
    Gollwitzer, Hans
    Harrasser, Norbert
    Stukenberg, Martin
    Prehn-Kristensen, Alexander
    PAIN PHYSICIAN, 2017, 20 (05) : 387 - 396
  • [34] Does different information disclosure on placebo control affect blinding and trial outcomes? A case study of participant information leaflets of randomized placebo-controlled trials of acupuncture
    Cheon, Soyeon
    Park, Hi-Joon
    Chae, Younbyoung
    Lee, Hyangsook
    BMC MEDICAL RESEARCH METHODOLOGY, 2018, 18
  • [35] Is a placebo-controlled surgical trial an oxymoron?
    Boyle, Krystene
    Batzer, Frances R.
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2007, 14 (03) : 278 - 283
  • [36] A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders
    Dunlop, B. W.
    Banja, J.
    JOURNAL OF MEDICAL ETHICS, 2009, 35 (06) : 384 - 389
  • [37] Ethics, methodology and the use of placebo controls in surgical trials
    Polgar, S
    Ng, J
    BRAIN RESEARCH BULLETIN, 2005, 67 (04) : 290 - 297
  • [38] Traditional Chinese medicine diagnosis and response to acupuncture for insomnia: An analysis of two randomized placebo-controlled trials
    Chung, Ka-Fai
    Yeung, Wing-Fai
    Leung, Feona Chung-Yin
    Zhang, Shi-Ping
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2016, 8 (05) : 797 - 801
  • [39] Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials
    Qiang Du
    Yan-Jun Wang
    Sheng Yang
    Yue-Yang Zhao
    Ping Han
    Advances in Therapy, 2014, 31 : 1182 - 1195
  • [40] Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials
    Mahr, Alfred
    Golmard, Clara
    Pham, Emilie
    Iordache, Laura
    Deville, Laure
    Faure, Pierre
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (07) : 731 - 741